IMPLEMENTATION OF SCIENTIFIC COSTING IN BULK DRUG AND R&D DEPARTMENT OF A PHARMA INDUSTRY Submitted By KAUSTUBH NIJASURE Under the guidance of Prof. P.M. Nayak A PROJECT SUBMITTED IN PART COMPLETITION OF MMS TO THE Vidyalankar Institute Of Technology Wadala (East)‚ Mumbai 400 031 JULY 14th‚ 2008 Executive summary: Centaur Pharmaceuticals Pvt. Ltd. has following divisions: 1. Bulk Drug 2. Formulations 3. Research and Development 4. Clinical Research
Premium Costs Cost Pharmacology
Ms. Adom Writing Seminar April 5‚ 2013 Happy When Others Are Jaime Montalvo has been all over the place. He has lived all over the world‚ and did not grow up in the greatest of conditions since his family was not the wealthiest by any means. However‚ Jaime holds a high standard for himself that has taken him places and will continue to take him places in life. My name is Jaime Montalvo‚ and I am a tennis professional at the Chapel Hill Country Club. Those who don’t know me well probably see me as
Premium Full-time Work ethic Employment
HEC006 Volume 4 Issue 1 March 2006 An ERP Story: Background (A) Case prepared by Professors Carmen BERNIER and Vital ROY‚ as well as Éric BRUNELLE Business Context In 1950‚ when the general insurance company Aux Bons Soins (ABS) was in its early days‚ it offered a full range of general insurance products for individuals residing in the province of Quebec. Over the years‚ Canada has seen a consolidation of its general insurance industry. Three years ago‚ ABS acquired the insurance company
Premium Management Project management
|OBJECTIVE OF THE STUDY |6 | |3 |NEED TO KNOW PHARMA INDUSTRY |7 | |4 |PHARMA INDUSTRY TODAY |7 | |5 |KEY ISSUE FOR PHARMACEUTICAL
Premium Pharmaceutical industry Pharmacology Generic drug
Scope of this report: The scope of the report was based on the annual reports & web site‚ input from interviews of executives of the SQUARE Pharmaceuticals Limited. To analyze the situation in question‚ we worked on focusing on SQUARE Pharmaceuticals Limited and analyzing their objectives‚ market strategies‚ market situations‚ product mixes‚ etc. The analysis was based on the exposed and available information only. In-depth data were not always available on-demand due to some unavailable reasons
Premium Marketing Pharmaceutical industry Pharmacology
representatives in Pharma companies and innovative ways to improve them. Overview: Attrition refers to the reduction in staff and employees of company by normal means. The primary focus is to present the high attrition rate seen in the pharmaceutical market industry‚ its causes and controlling strategy for retention of Pharma sales representatives. Though attrition is a natural phenomena in all industries‚ Indian Pharma marketing industries is worst plagued by it. After IT and BPO‚ Pharma marketing industries
Premium Sales
Corporate finance Project Corporate finance Project Sun pharmaceuticals Sun pharmaceuticals Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Type | Public | Traded as | BSE : 524715 NSE: sunpharma | Industry | Pharmaceuticals | Founded | 1983
Premium Pharmaceutical industry Pharmacology
HRM CASE STUDY ON NATIONAL PHARMA Strengths of the analysis of the Discussant 1 • Highlighted the interests and gains of various stakeholders • Highlighted the various deficiencies in execution of the program • Breaking up of problems into appropriate sections : right to information‚ right to be consulted and right to decide jointly • Emphasized the fact that proper research has not been done and how the strategy has been forced by the top management Strengths of the analysis of the Discussant
Premium Management Scientific method Feedback
KALYAN PHARMA LIMITED- CASE ANALYSIS PHARMA SECTOR BACKGROUND: In early 1930’s the medicines were dispensed by doctors and the concept of prescription was not present. Later on the prescription segment grew to 80% by 1970’s and the reason being that number of doctors increased to 250000 as opposed to 110000. Presently the sector is growing at the rate of 8% to 9%. Sales of products has increased from 70 billion to 150 billion. COMPANY BACKGROUND: In 1907‚ Kalyan Pharma Limited (KPL) was
Premium Marketing Sales
L. van der Broek Consumer Care G. Balkema Portfolio Management R. Scheitza* Medical Care A. Main Research A. Klausener Development F. J. Placke Industrial Operations & QHSE A. Noack Bayer Schering Pharma (BSP) A. Fibig BSP Regions International U. Köstlin BSP Global Drug Discovery A. Busch* BSP Global Development K. Malik Central Administration & Organization M. Vehreschild Product Supply H. Klusik S. E. Peterson
Premium Board of directors